Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

      Xtant Medical Logo

      News provided by

      Xtant Medical Holdings, Inc.

      Nov 16, 2026, 07:00 ET

      Share this article

      Share this article


      Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives.

      BELGRADE, Mont., Nov. 16, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2026.

      Third Quarter 2026 Financial Highlights

      • Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue.
      • Biologics revenue was $19.3 million for the third quarter of 2026, up 13% from the third quarter of 2025 and up 11% from the second quarter of 2026, third quarter 2026 revenue includes $2.2 million from sales of HEMOBLAST® Bellows.

      "The Board is disappointed with Xtant's financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable," said Stavros Vizirgianakis, Chairman of the Board. "Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board's interests are directly aligned with stockholders. The Board's priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year."

      The Board's active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required.

      Third Quarter 2026 Financial Results

      Revenue for the third quarter of 2026 was $24.3 million compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of $5.4 million of prior-year revenue from the divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Biologics revenue was $19.3 million, an increase of 13% from $17.1 million for the third quarter of 2025 and 11% from $17.4 million for the second quarter of 2026. Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement, a non-GAAP measure, grew 8% compared to the second quarter of 2026 and 6% compared to the third quarter of 2025.

      Gross margin for the third quarter of 2026 was 56.3%, compared to 66.1% for the same period in 2025. The decrease primarily reflected a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix.

      Operating expenses for the third quarter of 2026 were $16.7 million, compared to $19.5 million for the third quarter of 2025. General and administrative expenses decreased to $5.0 million from $7.1 million, due primarily to the divested non-core Coflex/CoFix assets and international hardware business and lower expense under compensation plans. Sales and marketing expenses decreased to $11.2 million from $11.7 million due primarily to savings related to the divestitures and lower consulting fees, partially offset by higher compensation expense from increased sales headcount, including sales personnel hired in connection with the Company's exclusive U.S. distribution agreement for HEMOBLAST, and by higher independent agent commissions and travel expenses.

      Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025.

      Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025.

      The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/ acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) is included in the financial tables at the end of this release.

      As of September 30, 2026, the Company had $7.8 million of cash and cash equivalents; $22 million of total indebtedness, consisting of $10.2 million of current and long-term debt and $11.8 million of borrowings under its revolving credit facility; and $2.1 million of availability under its revolving credit facility. As of December 31, 2025, the Company had $17.1 million of cash and cash equivalents; $25.4 million of total indebtedness, consisting of $14.5 million of current and long-term debt and $10.9 million of revolving credit borrowings; and $3.8 million of revolving credit availability.

      Based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months.

      2026 Financial Guidance

      Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. While the Board of Directors conducts its strategic review process, the Company is not providing revised full-year 2026 financial guidance. At the same time, as detailed elsewhere in this release, the Board is encouraged by the recent momentum in the Company's core biologics business and remains committed to scaling this franchise throughout the strategic review process.

      Conference Call

      Xtant Medical will not host a conference call or webcast to discuss its third quarter 2026 financial results. 

      About Xtant Medical Holdings, Inc.

      Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

      The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

      Non-GAAP Financial Measures

      To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including EBITDA, adjusted EBITDA, EBITDA and adjusted EBITDA as a percentage of total revenue, and biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are included in the tables at the end of this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

      Cautionary Statement Regarding Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "projects," "seeks," "aims," "goal," "strategy," "continue," "future," "will," "would," "should," "could," "may," "potential," "opportunity," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include, among others, statements regarding the recent momentum in the Company's core biologics products business and the Board's commitment to scaling that business; the Board's priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; the scope, timing, conduct and potential outcomes of the strategic review process; the Company's expectation that it will not achieve its previously issued full-year 2026 guidance; the Company's expectation that its cash and cash equivalents and availability under its revolving credit facility, will be sufficient to fund operations for at least the next 12 months; and the expected timing of the filing of the Company's Quarterly Report on Form 10-Q. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results, financial performance and need for additional capital; the Company's ability to sustain or increase revenue growth in its biologics business, including the possibility that recent growth trends will not continue; results of the Board's strategic review process, including the possibility that the process will not result in any strategic alternative, operational change, restructuring, transaction, initiative or other action, or that any action taken will not achieve its anticipated benefits or enhance stockholder value; the timing of the strategic review process and the possibility that it may be suspended, modified or terminated at any time; the Company's ability to identify, negotiate, finance, obtain any required approvals for and complete any strategic alternative, operational change, transaction, partnership, restructuring or other action on favorable terms or at all, and to implement successfully its strategic priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; risks associated with the strategic review process, including disruption and distraction of management, costs, and effects on employees, agents, customers, suppliers and other business relationships; the absence of financial guidance and the Company's inability to achieve its previously issued guidance; the Company's ability to generate operating cash flows and maintain availability under its revolving credit facility; the success of the Dilon distribution arrangement and the HEMOBLAST product and the possibility that the distribution agreement may be terminated and the effect of any such termination on the Company, its business and operating results; the ability of Dilon to continue to manufacture and supply the HEMOBLAST product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company's expanded field sales force to improve its reach and leverage its contract portfolio and independent agent network; other risks associated with acquisitions and dispositions; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products, including the absence of future license revenue resulting from changes in the reimbursement environment; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject, including any litigation relating to the strategic review process; the effect of product recalls and defects; its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt and comply with the covenants in its credit agreements, including the minimum liquidity and net revenue covenants, to obtain any needed future amendments or waivers, and to access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 to be filed with the SEC on or about November 16, 2026. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

      XTANT MEDICAL HOLDINGS, INC.

      Consolidated Balance Sheets

      (In thousands, except number of shares and par value)




      As of
      September 30, 2026



      As of

      December 31, 2025




      (Unaudited)





      ASSETS









      Current Assets:









      Cash and cash equivalents


      $

      7,793



      $

      17,053


      Restricted cash



      92




      275


      Trade accounts receivable, net of allowance for credit losses and
      doubtful accounts of $2,756 and $2,165, respectively



      18,823




      17,803


      Inventories



      32,503




      30,263


      Note receivable



      —




      10,462


      Prepaid and other current assets



      1,395




      2,389


      Total current assets



      60,606




      78,245


      Property and equipment, net



      5,449




      6,202


      Right-of-use asset, net



      2,738




      3,192


      Goodwill



      6,074




      6,074


      Intangible assets, net



      229




      299


      Other assets



      127




      133


      Total Assets


      $

      75,223



      $

      94,145











      LIABILITIES & STOCKHOLDERS' EQUITY









      Current Liabilities:









      Accounts payable


      $

      5,364



      $

      3,844


      Accrued liabilities



      7,699




      10,626


      Current portion of long-term debt



      4,770




      3,500


      Current portion of lease liability



      588




      622


      Current portion of finance lease obligations



      19




      35


      Line of credit



      11,833




      10,857


      Total current liabilities



      30,273




      29,484


      Long-term Liabilities:









      Lease liability, less current portion



      2,248




      2,665


      Finance lease obligation, less current portion



      —




      12


      Long-term debt, plus premium and less issuance costs



      5,436




      11,026


      Other liabilities



      7




      5


      Total Liabilities



      37,964




      43,192


      Commitments and Contingencies









      Stockholders' Equity:









      Preferred stock, $0.000001 par value; 10,000,000 shares
      authorized; no shares issued and outstanding



      —




      —


      Common stock, $0.000001 par value; 300,000,000 shares
      authorized; 140,452,061 shares issued and outstanding as of
      September 30, 2026 and 140,039,557 shares issued and
      outstanding as of December 31, 2025



      —




      —


      Additional paid-in capital



      307,810




      305,439


      Accumulated other comprehensive loss



      (1)




      —


      Accumulated deficit



      (270,550)




      (254,486)


      Total Stockholders' Equity



      37,259




      50,953


      Total Liabilities & Stockholders' Equity


      $

      75,223



      $

      94,145


      XTANT MEDICAL HOLDINGS, INC.

      Consolidated Statements of Operations

      (Unaudited, in thousands, except number of shares and per share amounts)




      Three Months Ended

      September 30,



      Nine Months Ended

      September 30,




      2026



      2025



      2026



      2025


      Revenue

















      Product revenue


      $

      24,285



      $

      27,772



      $

      68,200



      $

      87,492


      License revenue



      —




      5,483




      —




      14,078


      Total Revenue



      24,285




      33,255




      68,200




      101,570



















      Cost of Sales



      10,623




      11,263




      29,237




      35,051


      Gross Profit



      13,662




      21,992




      38,963




      66,519



















      Operating Expenses

















      General and administrative



      5,013




      7,071




      17,722




      22,082


      Sales and marketing



      11,181




      11,746




      29,735




      34,566


      Research and development



      496




      634




      1,626




      1,643


      Write-off of distribution agreement deposit



      —




      —




      5,000




      —


      Total Operating Expenses



      16,690




      19,451




      54,083




      58,291



















      (Loss) Income from Operations



      (3,028)




      2,541




      (15,120)




      8,228



















      Other Expense

















      Interest expense



      (590)




      (904)




      (1,731)




      (2,953)


      Interest income



      —




      —




      220




      —


      Unrealized foreign currency transaction
      (loss) gain



      (10)




      (56)




      12




      146


      Other income (expense)



      231




      (16)




      820




      (18)


      Total Other Expense



      (369)




      (976)




      (679)




      (2,825)



















      Net (Loss) Income from Operations
      Before Provision for Income Taxes



      (3,397)




      1,565




      (15,799)




      5,403



















      Provision for Income Taxes Current and
      Deferred



      (165)




      (257)




      (265)




      (487)


      Net (Loss) Income


      $

      (3,562)



      $

      1,308



      $

      (16,064)



      $

      4,916



















      Net (Loss) Income Per Share:

















      Basic


      $

      (0.03)



      $

      0.01



      $

      (0.11)



      $

      0.04


      Diluted


      $

      (0.03)



      $

      0.01



      $

      (0.11)



      $

      0.03



















      Shares used in the computation:

















      Basic



      140,363,595




      139,712,969




      140,228,117




      139,366,489


      Diluted



      140,363,595




      150,377,234




      140,228,117




      149,912,292


      XTANT MEDICAL HOLDINGS, INC.

      Consolidated Statements of Cash Flows

      (Unaudited, in thousands)




      Nine Months Ended
      September 30,




      2026



      2025


      Operating activities:









      Net (loss) income


      $

      (16,064)



      $

      4,916


      Adjustments to reconcile net (loss) income to net cash (used in) provided by
      operating activities:









      Depreciation and amortization



      1,525




      3,404


      Loss (gain) on sale of fixed assets



      —




      (16)


      Non-cash interest



      380




      415


      Stock-based compensation



      2,451




      2,165


      Provision for reserve on accounts receivable



      987




      568


      Provision for excess and obsolete inventory



      2,904




      1,318


      Write-off of distribution agreement deposit



      5,000




      —


      Other



      4




      68











      Changes in operating assets and liabilities:









      Accounts receivable



      (2,007)




      (5,639)


      Inventories



      (4,215)




      (2,789)


      Prepaid and other assets



      166




      314


      Accounts payable



      1,519




      (1,279)


      Accrued liabilities



      (2,927)




      3,721


      Net cash (used in) provided by operating activities



      (10,277)




      7,166











      Investing activities:









      Purchases of property and equipment



      (830)




      (1,987)


      Proceeds from sale of fixed assets



      129




      206


      Distribution agreement deposit



      (5,000)




      —


      Proceeds from divestitures



      10,368




      5,000


      Net cash provided by investing activities



      4,667




      3,219











      Financing activities:









      Borrowings on line of credit



      51,879




      77,573


      Repayments on line of credit



      (50,902)




      (78,385)


      Payments on long-term debt



      (4,701)




      (5,000)


      Debt issuance costs



      —




      (49)


      Payments on financing leases



      (27)




      (51)


      Payment of taxes from withholding of common stock on settlement of restricted
      stock units



      (80)




      (116)


      Net cash used in financing activities



      (3,831)




      (6,028)











      Effect of exchange rate changes on cash and cash equivalents and restricted cash



      (2)




      63











      Net change in cash and cash equivalents and restricted cash



      (9,443)




      4,420


      Cash and cash equivalents and restricted cash at beginning of period



      17,328




      6,221


      Cash and cash equivalents and restricted cash at end of period


      $

      7,885



      $

      10,641


      Reconciliation of cash and cash equivalents and restricted cash reported in the
      condensed consolidated balance sheets









      Cash and cash equivalents


      $

      7,793



      $

      10,400


      Restricted cash



      92




      241


      Total cash and restricted cash reported in condensed consolidated balance sheets


      $

      7,885



      $

      10,641


      XTANT MEDICAL HOLDINGS, INC.

      CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA

      (in thousands)




      Three Months Ended

      September 30,



      Nine Months Ended

      September 30,




      2026



      2025



      2026



      2025



















      Net (Loss) Income


      $

      (3,562)



      $

      1,308



      $

      (16,064)



      $

      4,916



















         Depreciation and amortization



      483




      1,161




      1,525




      3,404


         Interest expense, net



      590




      904




      1,511




      2,953


         Tax expense



      165




      257




      265




      487


         Non-GAAP EBITDA



      (2,324)




      3,630




      (12,763)




      11,760



















         Net (Loss) Income/Total Revenue



      (14.7)

      %



      3.9

      %



      (23.6)

      %



      4.8

      %


















         Non-GAAP EBITDA/Total Revenue



      (9.6)

      %



      10.9

      %



      (18.7)

      %



      11.6

      %


















      NON-GAAP ADJUSTED EBITDA CALCULATION

















         Non-cash compensation



      830




      641




      2,451




      2,165


         Write-off of distribution agreement deposit



      —




      —




      5,000




      —


         Divestiture/acquisition-related expenses



      (94)




      74




      (612)




      369


         Acquisition-related fair value adjustments



      37




      140




      132




      311


         Unrealized foreign currency translation loss (gain)



      10




      56




      (12)




      (146)


         Separation related expenses



      69




      —




      69




      23



















         Non-GAAP Adjusted EBITDA


      $

      (1,472)



      $

      4,541



      $

      (5,735)



      $

      14,482



















         Non-GAAP Adjusted EBITDA/Total
      Revenue



      (6.1)

      %



      13.7

      %



      (8.4)

      %



      14.3

      %

      XTANT MEDICAL HOLDINGS, INC.

      RECONCILIATION OF NON-GAAP BIOLOGICS PRODUCT REVENUE GROWTH

      (in thousands)




      Three Months Ended






       September 30,
      2026


      June 30,

      2026


      % Increase
      (Decrease)


         Total Revenue


      $

      24,285


      $

      23,031





      License Revenue



      —



      —





      Hardware Revenue



      4,944



      5,671





         Biologics Revenue



      19,341



      17,360
















      Sales related to HEMOBLAST and products affected by the
      market for wound care reimbursement



      2,204



      1,518





      Biologics product revenue excluding HEMOBLAST and
      products affected by the market for wound care reimbursement


      $

      17,137


      $

      15,842



      8

      %




      Three Months Ended






       September 30,
      2026


      September 30,
      2025


      % Increase
      (Decrease)


         Total Revenue


      $

      24,285


      $

      33,255





      License Revenue



      —



      5,483





      Hardware Revenue



      4,944



      10,623





         Biologics Revenue



      19,341



      17,149
















      Sales related to HEMOBLAST and products affected by the
      market for wound care reimbursement



      2,204



      935





      Biologics product revenue excluding HEMOBLAST and
      products affected by the market for wound care reimbursement


      $

      17,137


      $

      16,214



      6

      %

      SOURCE Xtant Medical Holdings, Inc.

      Modal title

      Also from this source

      Xtant Medical to Announce Third Quarter 2026 Financial Results on November 16, 2026

      Xtant Medical to Announce Third Quarter 2026 Financial Results on November 16, 2026

      Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic...

      Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

      Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

      Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal,...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.